EUVIMEDEUVIMED entdecken
Crossref

Semaglutide reduces drinking in adults with alcohol use disorder and obesity

The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 1-6

DOI: 10.1002/pu.31472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .

Zitieren

APA

(2026). Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update, 37(8), 1-6. https://doi.org/10.1002/pu.31472

Vancouver

Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update. 2026;37(8):1-6. doi:10.1002/pu.31472

BibTeX
@article{euvimed2026,
  title = {Semaglutide reduces drinking in adults with alcohol use disorder and obesity},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {1--6},
  doi = {10.1002/pu.31472}
}
Kostenlos starten →